Cost regulators for the National Health Service in England and Wales are rejecting the use of Roche’s Perjeta to treat certain forms of breast cancer.
News
Horizon picks up interferon gamma-1b rights from Boehringer
Dublin-Ireland based biopharma Horizon Pharma has bagged rights to Boehringer Ingelheim’s interferon gamma-1b in an around 30 countries primarily in Europe and the Middle East for 25 million euros.
Internis launches GI friendly alendronate formulation
Internis Pharma Binosto is now widely available across the UK, offering patients with osteoporosis the chance to access the first buffered formulation of alendronate designed to minimise gastrointestinal side effects commonly linked with traditional versions of the drug.
Marketer of the Year open for entries
Marketer of the Year identifies and benchmarks marketing talent within pharma organisations against the wider industry. Entries now open!
AZ Lynparza misses the mark in PhIII gastric cancer trial
AstraZeneca’s Lynparza has failed to hit targets in a Phase III trial assessing its effect on survival in patients with advanced gastric cancer.
Agreement reached in junior doctors contract dispute
An end to the long-running dispute between the government and the British Medical Association over the junior doctors contract is now in sight after both sides agreed a new deal.
Green light for Genentech’s cancer immunotherapy
Genentech’s immunotherapy Tecentriq has won an accelerated US Food and Drug Administration approval for a specific type of bladder cancer.
O’Neill unveils final AMR plan of attack
Lord Jim O’Neill is recommending that pharmaceutical firms are given a $1-billion bonus for each new antibiotic they discover, as part of an attack plan against the global threat of antimicrobial resistance, which could eventually kill more people than cancer.
AZ’ benralizumab cut asthma exacerbations in PhIII trial
AstraZeneca says that its investigational respiratory biologic benralizumab has turned in another successful performance in clinical trials, significantly reducing asthma exacerbations compared to a placebo.
Epstein leaves Novartis as pharmaceuticals splits in two
Novartis has announced plans to divide its pharmaceuticals division into two business units, in a restructure that also sees the departure of current division head and chief executive David Epstein.
Most healthcare professionals back pharma’s transparency drive
Pharma industry representatives say that the majority of healthcare professionals are still in support of its drive for greater transparency, backing the notion of payment declarations.
European approval for Actelion’s Uptravi in PAH
EU regulators have issued a green light for Actelion’s Uptravi, offering a new treatment option to patients with pulmonary arterial hypertension.
International Clinical Researcher of the Year 2016 winners revealed
PharmaTimes Media recognised top clinical researchers with a spectacular awards ceremony at the Lancaster London last night.
Novartis’ inhaler beats GSK’s Seretide on cutting COPD measure
The New England Journal of Medicine has published a clinical trial showing that Novartis’ Ultibro Breezhaler outshone GlaxoSmithKline’s Seretide on reducing COPD flare-ups, which could challenge the current reliance on inhaled corticosteroids.
Pfizer to spend $4.2bn on Anacor
Pfizer is spending around $4.2 billion on the purchase of Anacor Pharmaceuticals, thus securing access to the firm’s flagship non-steroidal topical PDE4 inhibitor crisaborole
